Nephrotoxicity as a dose-limiting factor in a high-dose cisplatin-based chemoradiotherapy regimen for head and neck carcinomas

Cancers

Volumn 8, Issue 2, 2016, Pages

  Hoek, Jantien ^a   Bloemendal, Karen M ^a   van der Velden, Lilly Ann A ^b   van Diessen, Judi N A ^a   van Werkhoven, Erik ^a   Klop, Willem M C ^a   Tesselaar, Margot E T ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chemoradiotherapy; Cisplatin; Head and neck cancer; Nephrotoxicity

Indexed keywords

CISPLATIN; CREATININE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GAMMA RADIATION; HEAD AND NECK CARCINOMA; HUMAN; HYPOPHARYNX CARCINOMA; LARYNX CARCINOMA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; NASOPHARYNX CARCINOMA; NEPHROTOXICITY; OROPHARYNX CARCINOMA; OUTCOME ASSESSMENT; PARANASAL SINUS CARCINOMA; PAROTID GLAND CARCINOMA; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 84958745746     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers8020021     Document Type: Article

References (24)

1. Furness, S.; Glenny, A.M.; Worthington, H.V.; Pavitt, S.; Oliver, R.; Clarkson, J.E.; Macluskey, M.; Chan, K.K.; Conway, D.I. Interventions for the treatment of oral cavity and oropharyngeal cancer: Chemotherapy. Cochrane Database Syst. Rev. 2010, 4, CD006386.
2. Pignon, J.P.; le Maître, A.; Maillard, E.; Bourhis, J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009, 92, 4-14.
3. Bourhis, J.; Sire, C.; Graff, P.; Grégoire, V.; Maingon, P.; Calais, G.; Gery, B.; Martin, L.; Alfonsi, M.; Desprez, P. et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): An open-label phase 3 randomised trial. Lancet Oncol. 2012, 13, 145-153.
4. Pignon, J.P.; Bourhis, J.; Domenge, C.; Designé, L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. Lancet 2000, 355, 949-955.
5. Budach, W.; Hehr, T.; Budach, V.; Belka, C.; Dietz, K. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 2006, 6, 28.
6. Adelstein, D.J.; Li, Y.; Adams, G.L.; Wagner, H., Jr.; Kish, J.A.; Ensley, J.F.; Schuller, D.E.; Forastiere, A.A. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J. Clin. Oncol. 2003, 21, 92-98.
7. Forastiere, A.A.; Goepfert, H.; Maor, M.; Pajak, T.F.; Weber, R.; Morrison, W.; Glisson, B.; Trotti, A.; Ridge, J.A.; Chao, C. et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N. Engl. J. Med. 2003, 349, 2091-2098.
8. Browman, G.P.; Hodson, D.I.; Mackenzie, R.J.; Bestic, N.; Zuraw, L. Cancer Care Ontario Practice Guideline Initiative Head and Neck Cancer Disease Site Group, Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: A systematic review of the published literature with subgroup analysis. Head Neck 2001, 23, 579-589.
9. Fan, K.Y.; Gogineni, H.; Zaboli, D.; Lake, S.; Zahurak, M.L.; Best, S.R.; Levine, M.A.; Tang, M.; Zinreich, E.S.; Saunders, J.R. et al. Comparison of acute toxicities in two primary chemoradiation regimens in the treatment of advanced head and neck squamous cell carcinoma. Ann. Surg. Oncol. 2012, 19, 1980-1987.
10. Rades, D.; Kronemann, S.; Meyners, T.; Bohlen, G.; Tribius, S.; Kazic, N.; Schroeder, U.; Hakim, S.G.; Schild, S.E.; Dunst, J. Comparison of four cisplatin-based radiochemotherapy regimens for nonmetastatic stage III/IV squamous cell carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 2011, 80, 1037-1044.
11. Rasch, C.R.; Hauptmann, M.; Balm, A.J. Intra-arterial chemotherapy for head and neck cancer: Is there a verdict? Cancer 2011, 117, 874.
12. Espeli, V.; Zucca, E.; Ghielmini, M.; Giannini, O.; Salatino, A.; Martucci, F.; Richetti, A. Weekly and 3-weekly cisplatin concurrent with intensity-modulated radiotherapy in locally advanced head and neck squamous cell cancer. Oral Oncol. 2012, 48, 266-271.
13. Cockcroft, D.W.; Gault, M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16, 31-41.
14. Dos Santos, N.A.; Carvalho Rodrigues, M.A.; Martins, N.M.; dos Santos, A.C. Cisplatin-induced nephrotoxicity and targets of nephroprotection: An update. Arch Toxicol 2012, 86, 1233-1250.
15. Rades, D.; Fehlauer, F.; Sheikh-Sarraf, M.; Kazic, N.; Basic, H.; Poorter, R.; Hakim, S.G.; Schild, S.E.; Dunst, J. Toxicity of two cisplatin-based radiochemotherapy regimens for the treatment of patients with stage III/IV head and neck cancer. Head Neck 2008, 30, 235-241.
16. Strojan, P.; Vermorken, J.B.; Beitler, J.J.; Saba, N.F.; Haigentz, M.; Bossi, P., Jr.; Worden, F.P.; Langendijk, J.A.; Eisbruch, A.; Mendenhall, W.M. et al. Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review. Head Neck 2015.
17. Hoebers, F.J.; Heemsbergen, W.; Balm, A.J.; van Zanten, M.; Schornagel, J.H.; Rasch, C.R. Concurrent chemoradiation with daily low dose cisplatin for advanced stage head and neck carcinoma. Radiother. Oncol. 2007, 85, 42-47.
18. Santoso, J.T.; Lucci, J.A., 3rd; Coleman, R.L.; Schafer, I.; Hannigan, E.V. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: A randomized trial. Cancer Chemother. Pharmacol. 2003, 52, 13-18.
19. Romesser, P.B.; Romanyshyn, J.C.; Schupak, K.D.; Setton, J.; Riaz, N.; Wolden, S.L.; Gelblum, D.Y.; Sherman, E.J.; Kraus, D.; Lee, N.Y. Percutaneous endoscopic gastrostomy in oropharyngeal cancer patients treated with intensity-modulated radiotherapy with concurrent chemotherapy. Cancer 2012, 118, 6072-6078.
20. Muraki, K.; Koyama, R.; Honma, Y.; Yagishita, S.; Shukuya, T.; Ohashi, R.; Takahashi, F.; Kido, K.; Iwakami, S.; Sasaki, S. et al. Hydration with magnesium and mannitol without furosemide prevents the nephrotoxicity induced by cisplatin and pemetrexed in patients with advanced non-small cell lung cancer. J. Thorac. Dis. 2012, 4, 562-568.
21. Morgan, K.P.; Buie, L.W.; Savage, S.W. The role of mannitol as a nephroprotectant in patients receiving cisplatin therapy. Ann. Pharmacother. 2012, 46, 276-281.
22. Morgan, K.P.; Snavely, A.C.; Wind, L.S.; Buie, L.W.; Grilley-Olson, J.; Walko, C.M.; Weiss, J. Rates of renal toxicity in cancer patients receiving cisplatin with and without mannitol. Ann. Pharmacother. 2014.
23. Li, Q.; Guo, D.; Dong, Z.; Zhang, W.; Zhang, L.; Huang, S.M.; Polli, J.E.; Shu, Y. Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs). Toxicol. Appl. Pharmacol. 2013, 273, 100-109.
24. Rubera, I.; Duranton, C.; Melis, N.; Cougnon, M.; Mograbi, B.; Tauc, M. Role of CFTR in oxidative stress and suicidal death of renal cells during cisplatin-induced nephrotoxicity. Cell Death Dis. 2013, 4, e817.